DRW Securities’s Haemonetics HAE Stock Holding History

DRW Securities’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-3,013	Closed	-$300K	–	235
2020 Q1	$300K	Buy	+3,013	New	+$327K	0.01%	212

Other funds holding HAE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DRW Securities's HAE Position: Q2 2020 in Review

DRW Securities sold out of Haemonetics (HAE) in Q2 2020, closing a stake of 3,013 shares — an estimated $300K sold.

DRW Securities first reported a position in HAE in Q1 2020 and held it in 1 quarter. The position peaked at $300K in Q1 2020. 285 funds tracked by Wall St. Rank hold HAE as of Q2 2020.

DRW Securities reported no remaining Haemonetics position as of Q2 2020 after selling out during the quarter.
DRW Securities sold 3,013 Haemonetics shares in Q2 2020, an estimated $300K.
DRW Securities first reported a position in Haemonetics in Q1 2020 and held it in 1 quarter.
DRW Securities's Haemonetics position peaked at $300K in Q1 2020.
285 funds tracked by Wall St. Rank held Haemonetics as of Q2 2020.

Based on DRW Securities's 13F filing for Q2 2020, filed 14 Aug 2020.